Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Neuropsychiatric Disorders Treatment Companies

Several companies are involved in the research, development, and commercialization of treatments for neuropsychiatric disorders. Neuropsychiatric disorders encompass a broad range of conditions affecting the central nervous system, including mental health disorders.

Neuropsychiatric Disorders and Treatment Companies


Latest Neuropsychiatric Disorders and Treatment Companies Update:

Eleusis Therapeutics (US) Received Breakthrough Therapy Designation from the FDA for its ketamine-based treatment for major depressive disorder, accelerating the development process. Entered into a strategic partnership with Otsuka Pharmaceutical Co. Ltd. for the global development and commercialization of its lead candidate.

Compass Pathways (UK) Announced positive Phase 2b results for psilocybin therapy in treatment-resistant depression, demonstrating significant improvements in patients' symptoms. Partnering with leading academic institutions to explore the use of psychedelic medicines for other mental health conditions like anxiety and addiction.

Roche (Switzerland) Launched Vraylar® (cariprazine) for bipolar depression in the US, offering a new treatment option with a different mechanism of action compared to traditional antidepressants. Invested in research and development of antipsychotic medications with neurodegenerative disease prevention potential.

Johnson & Johnson (US) Completed the acquisition of Akili, a digital health company developing video game-based therapeutics for ADHD and other neuropsychiatric disorders. Announced plans to expand its Janssen Neuroscience division with a focus on developing innovative therapies and digital solutions for brain health.

List of Neuropsychiatric Disorders and Treatment Key companies in the market

  • AstraZeneca (U.K.)

  • GlaxoSmithKline (U.K.)

  • Universal Health Services Inc. (U.S.)

  • Biogen (U.S.)

  • Boehringer Ingelheim GmbH (Germany)

  • Eli Lilly (U.S.)

  • Bristol-Meyer Squibb (U.S.)

  • Johnson & Johnson (U.S.)

  • Pfizer (U.S.)

  • Wyeth (U.S.)

  • Otsuka Holdings Co. Ltd (Japan)

  • Astellas Pharma Inc. (Japan)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.